Neoadjuvant chemotherapy (NCT) is a standard of care for locally advanced and initially inoperable breast cancer. NCT can test chemotherapy efficacy and can be followed by breast-conserving surgery. Considering taxanes as one of the most effective agents, we analyzed the efficacy of a neoadjuvant schedule without anthracyclines and based only on taxanes and carboplatin, trying to avoid cardiotoxicity, which is the most serious side effect correlated with anthracyclines.
Anthracycline-free neoadjuvant chemotherapy ensures higher rates of pathologic complete response in breast cancer / DE IULIIS, Francesca; Salerno, Gerardo; Corvino, Raffaella; D'Aniello, Debora; Cefalì, Katia; Taglieri, Ludovica; Lanza, Rosina; Scarpa, Susanna. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - 17:1(2017), pp. 34-40. [10.1016/j.clbc.2016.06.010]
Anthracycline-free neoadjuvant chemotherapy ensures higher rates of pathologic complete response in breast cancer
SALERNO, GERARDO;Taglieri, Ludovica;SCARPA, Susanna
2017
Abstract
Neoadjuvant chemotherapy (NCT) is a standard of care for locally advanced and initially inoperable breast cancer. NCT can test chemotherapy efficacy and can be followed by breast-conserving surgery. Considering taxanes as one of the most effective agents, we analyzed the efficacy of a neoadjuvant schedule without anthracyclines and based only on taxanes and carboplatin, trying to avoid cardiotoxicity, which is the most serious side effect correlated with anthracyclines.| File | Dimensione | Formato | |
|---|---|---|---|
|
De Iuliis_Anthracycline-Free_2017.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.89 MB
Formato
Adobe PDF
|
1.89 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
